pharma and the news

the six-billion-dollar ask

Direct-to-consumer prescription-drug advertising grew from $1.3 billion in 1997 to $6.0 billion in 2016, both in 2016 dollars — and from 79,000 ads a year to 4.6 million, including 663,000 television commercials [1]. The federal continuation: manufacturers spent $17.8 billion on DTC advertising for 553 drugs across 2016–2018, roughly stable at about $6 billion a year, with nearly two-thirds of it concentrated on just 39 drugs — about half of them for chronic conditions including arthritis, diabetes, and depression [2].

Where the money goes is the structural fact this page keeps returning to: drug television advertising was about 76% of total DTC spending — $13.4 billion of the $17.8 billion — during 2016–2018 [2]. The concentration on TV is extreme: only 113 of the 553 advertised drugs ran TV ads at all [2].

Three different numbers circulate as “drug ad spending,” and they are not the same number. $29.9 billion (2016) is all medical marketing, most of it aimed at health professionals, not consumers. $9.6 billion is all DTC advertising, including disease-awareness campaigns, health services, and lab tests. $6.0 billion is DTC prescription-drug advertising — the number this page means when it says “drug ads” [1]. The popular press routinely swaps these; check which one a sentence needs before quoting it.

The rebuttal that must sit beside those markers. The same peer-reviewed literature that documents the surge also documents that “the initial surge in direct-to-consumer advertising preceded the 1997 FDA guidelines” and that the guidelines “may not have been the most important reason” for the overall increase — DTC spending tripled from 1996 to 2000, reaching nearly $2.5 billion, and even then was only about 15% of total drug promotion [5]. The markers on this chart say the rules changed here. They do not say the rules caused the curve, because that claim outruns the evidence.

What the 1997 guidance actually did is narrower and stranger than the folklore. DTC advertising was never illegal — FDA's own 1997 notice records that it “has been practiced by the prescription drug industry since the early 1980's” [3]. Under the statute and regulation (21 U.S.C. 352(n); 21 CFR 202.1(e)(1)), a broadcast ad naming a drug and its use must include a “major statement” of major risks and either present the full “brief summary” of risk information — impractical in a 60-second spot — or make “adequate provision” for disseminating the approved labeling. In FDA's own words: “Previously, FDA had not described how prescription drug and biological product sponsors could fulfill the ‘adequate provision’ requirement for consumer-directed broadcast advertising” [3]. The guidance described an approach that satisfies it — a toll-free number, a concurrent print ad or brochure, referral to a health provider, a web address — and product-claim TV ads became commercially practical. By 1999, FDA itself wrote that “this draft guidance had a substantial impact on the direct-to-consumer broadcast environment” [4]. The agency characterizes the impact; this page does not have to.

Why the chart ends where it does, and what it is built on. No federal agency publishes a DTC advertising spend series. The peer-reviewed anchor is an analysis of Kantar Media industry tracker data [1]; the federal continuation is a GAO analysis of Nielsen Media tracker data [2]. Post-2018 numbers exist only from industry trackers directly, with no federal or peer-reviewed continuation — so the series on this page ends at 2018, and the two JAMA endpoints are drawn without a connecting line because the year-by-year values live in a paywalled supplement we could not verify at build time. The eight verified figures behind this section are downloadable as CSV (CC BY 4.0): resolv-dtc-ad-spend.csv.

two countries

The United States and New Zealand are the only countries in the industrialized world that permit direct-to-consumer advertising of prescription medicines that includes product claims [6][7]. Every word in that sentence is load-bearing, and the popular versions fail by dropping one:

• “Product claims” — Canada legally allows ads that mention “either the product or the indication, but not both” [6]: reminder ads (drug name, no claim) and help-seeking ads (condition, no name). So “drug ads are illegal in Canada” is false as stated.
• “Industrialized world” — legal status and enforcement in some non-OECD jurisdictions is murkier, so the flat “only two countries on Earth” is an overreach the sourced claim does not need [7].
• “Prescription” — over-the-counter drug advertising is broadly legal worldwide. “The only two countries where drug ads are legal” is false on its face.

Two context points keep the claim honest. The EU considered even a limited relaxation in 2008 and rejected it, 22 of 27 member states against [6]. And New Zealand's status is legislative permissiveness — a Medicines Act passed in 1981, before the modern debate — rather than an affirmative policy endorsement; New Zealand's own medical profession has documented its opposition [7].

“ask your doctor” works — in both directions

The strongest single piece of evidence on this page is a randomized controlled trial: 298 unannounced standardized-patient visits to 152 primary-care physicians, with trained actors presenting either major depression or adjustment disorder — a condition where antidepressants are not clearly indicated — and making a brand-specific request (“I saw this ad for Paxil…”), a general request for medication, or no request [8].

Read the first row and the last row together, because both are the finding. A brand-name request quintupled prescribing for a questionable indication (55% vs 10%). And a request — any request — cut undertreatment of real depression: minimally acceptable initial care went from 56% of no-request visits to 90–98% when patients asked. The authors' own conclusion carries both: DTC advertising “may have competing effects on quality, potentially both averting underuse and promoting overuse” [8]. A version of this story that gives you only one row is arguing, not informing.

The chain, kept explicit. The trial tests patient requests, not ads. The ads→requests link is the review tier: DTC advertising increases prescribing volume and patient demand, and shifts prescribing, with additional evidence of shifts toward less appropriate prescribing and less cost-effective treatment; claimed benefits for adherence “do not stand up to scrutiny,” and there is no evidence of improved treatment quality or earlier provision of needed care [9]. So the documented chain is ads → requests → prescribing, with each link cited separately — not “ads make doctors prescribe,” which skips a link the evidence keeps explicit.

how the news covered the drugs

Coverage quality has been measured — three peer-reviewed content analyses, three countries, one pattern: benefits inflated, harms omitted, conflicts undisclosed. None of these studies measures why; that distinction matters and this page returns to it in the next section.

• United States, NEJM 2000 — 180 newspaper articles and 27 TV reports (1994–1998) on three widely used drugs: 40% of stories gave no quantitative benefit; of those that did, 83% reported relative benefits only (3% absolute only, 15% both). Only 47% mentioned potential harms; 30% mentioned cost. And the load-bearing finding: of 170 stories citing an expert or a study, 50% cited at least one with a disclosed financial tie to the drug's manufacturer — and only 39% of those stories disclosed the tie [10].
• United States, PLoS Medicine 2008 — 500 health-news stories evaluated against standardized criteria by HealthNewsReview.org. The author's own summary: “between 62%-77% of stories failed to adequately address costs, harms, benefits, the quality of the evidence, and the existence of other options.” Per criterion: costs 77%, quantifying benefits 72%, harms 67%, quality of evidence 65%, alternatives 62% — and about half failed the independent-sources-and-conflicts criterion [11].
• Canada, CMAJ 2003 — 193 articles across 24 large Canadian dailies (2000) on five new drugs: 68% made no mention of side effects or harms; 62% gave no quantification of benefits or harms; 4% mentioned contraindications. And the conflict finding again: excluding industry and government spokespeople, potential financial conflicts were mentioned for only 3% (5 of 164) of quoted interviewees [12].

Different countries, different methods, different decades — and the same three failures. That replication is what makes this section evidence rather than anecdote. What it is not evidence of is a cause. Which brings us to the number everyone asks for.

the number nobody publishes

The obvious question is: how much of a news division's advertising revenue comes from pharmaceutical companies? No public accounting of that number exists. No federal agency publishes ad revenue by category and daypart, and no peer-reviewed estimate has been published. The figures that circulate — “pharma buys 30% of evening-news ad minutes,” “70–75% of TV news is pharma-funded” — trace to industry-tracker press quotes or to nothing at all, and the viral personalization of the claim is fact-checked False: PolitiFact rated “Pfizer is paying Anderson Cooper $12 million” False in June 2023 [16]. This page will not echo any of those figures, including as “questions being asked.”

That opacity is itself the finding. The one side of the ledger that is public is the industry's: about 76% of DTC drug-ad dollars — roughly $4.5 billion a year in 2016–2018 — went to television [2]. The other side, what any given news operation receives, is published nowhere. An industry's dependence on television is documented to the billion; television's dependence on that industry is not documented at all.

The second honest absence: the causal literature does not exist. There is no robust empirical literature linking pharmaceutical advertising revenue at a news outlet to that outlet's drug-safety coverage decisions — we searched for it, in multiple phrasings, and it is not there. The classic ad-revenue-versus-coverage studies are about tobacco, a different industry, and are not presented as pharma evidence here. So what this page can honestly show is: measured coverage failures (section above), a described incentive structure (this section), and no established causal link between them. If you have seen the claim “media buries drug harms because pharma pays them” stated as fact, you have seen someone publish beyond the evidence.

Where advertiser pressure is documented with primary sources, it is professional media — medical journals — not consumer news, and the domain label matters. In 1992, Annals of Internal Medicine published an expert review of all 109 full-page drug ads in ten leading journals against FDA standards [14]. In the aftermath, several large pharmaceutical companies withdrew advertising from the journal — an estimated $1–1.5 million in lost revenue — and coeditors Robert and Suzanne Fletcher resigned in 1993 [13]. Robert Fletcher, on the record:

“The pharmaceutical industry showed us that the advertising dollar could be a two-edged sword, a carrot or a stick. If you ever wondered whether they play hardball, that was a pretty good demonstration that they do.”— Robert Fletcher, former coeditor, Annals of Internal Medicine, quoted in PLoS Medicine 2006 [13]

A second journal-side instance: in the early 1980s Eli Lilly threatened the BMJ with legal action over papers on benoxaprofen side effects, then “backtracked hastily” [15]. And the structural dependence the pressure runs on is quantified for professional media in a way it never has been for news: in 2004, advertising was 15.1% of total American Medical Association revenues ($40.7 million — more than double its subscription income), and in 1996 five of six physician organisations studied drew at least 10% of annual revenue from pharmaceutical advertising [13].

What this page is NOT claiming with those cases. The Annals and BMJ episodes are medical-journal cases. No adjudicated case — a court record, a FOIA document — of a pharmaceutical advertiser dictating a US consumer news outlet's editorial content surfaced in the searches behind this page. That absence is a publishable sentence, and this is it. Presenting the journal cases as news-media cases would be exactly the kind of overreach this site exists to avoid.

The watchdog's own history is now citable, so here it is rather than the observation we previously had to settle for. HealthNewsReview.org — the project that graded the 500 stories in the study above — was launched in 2006 by Gary Schwitzer, a former CNN health reporter then at the University of Minnesota, and ceased publishing reviews at the end of 2018 when its grant funding ran out [24][25]. Twelve years, more than 6,000 articles, and a funding chain that tells its own story: an informed-medical-decisions foundation whose successor pulled support in 2013, then a private foundation's $1.3 million grant from 2014 that was not renewed [24]. The systematic public grading of US health news stopped there, and nothing has replaced it since.

So here is the structure, described once, plainly. Television news divisions sell airtime. The pharmaceutical industry buys roughly three-quarters of its multi-billion-dollar consumer ad budget as airtime [2]. The same news operations' health desks cover those advertisers' products, and the measured record of that coverage — across three countries — shows benefits inflated, harms omitted, and sources' financial conflicts mostly undisclosed [10][11][12]. No disclosure requirement, no federal dataset, and no peer-reviewed study connects the two facts, and this page does not connect them either. The money is documented, the coverage is measured, and the space between them is undocumented — which is exactly what you now know.

the cold of the soul

The most-told story about drug marketing and public belief is Japan's. In Crazy Like Us, Ethan Watters devotes a chapter to it — “The Mega-Marketing of Depression in Japan” — and argues that a market for depression there was built rather than found [17]. It is the single best narrative illustration of everything above, which is exactly why it deserves to be checked rather than repeated.

We checked it. The core is real, and the popular retelling has the sequence backwards.

Start with what is solidly documented. Japan approved its first SSRI, fluvoxamine, in 1999 — roughly a decade after such drugs became routine in the United States [18]. The marketing that followed was studied at the time by an anthropologist, Kalman Applbaum, who published an account of the SSRI push in Japan in a Duke University Press volume on global pharmaceuticals [19]. Applbaum is the checkable scholarship underneath Watters's narrative, and his argument is structural: firms expand markets by drawing nominally independent professionals into their distribution channel. Watters relays Applbaum's interview material with drug-company executives; Applbaum did the fieldwork.

Now the problem, and it is a big one: the dates do not run the way the story needs them to. Japanese suicides passed 30,000 in a year for the first time in 1998, and public attention to depression rose in response [18]. The first SSRI arrived in 1999. A history of Japanese depression concepts published in 2025 states it plainly: the suicide spike came first, and social interest followed it. The marketing did not arrive at an indifferent country and manufacture a concern. It arrived at a country that had just had a very public reason to be worried.

The second correction is larger. The Japanese anthropologist Junko Kitanaka wrote the book-length ethnography of this same episode, and she directly questions the premise that Japan had no depression before Western drugs — her work states that Japanese medicine did have a language for talking about it [20]. Japanese psychiatry ran its own indigenous concept of depression from roughly 1960 to 2000, descended from German and Swiss psychiatry, with roots in the late nineteenth century [18]. Japan did not lack a concept of depression. It had a different one, and an American concept displaced it. That is a real and interesting claim, and it is not the same claim as “a drug company invented Japanese depression.”

Kitanaka's account puts the weight somewhere else entirely: on overwork. In 2000, Japan's Supreme Court ordered an employer to pay compensation for an employee's suicide caused by long and excessive overwork [21]. Depression became discussable in Japan substantially through labour litigation — a route with no drug company in it at all.

“Thanks to these marketing practices, antidepressant sales have increased six fold, from ¥14.5 billion in 1998 to ¥87 billion in 2006.”— Hiroshi Ihara, “A cold of the soul: a Japanese case of disease mongering in psychiatry,” International Journal of Risk & Safety in Medicine, 2012 [22]

That is the famous number, and here is what we can and cannot say about it. It is traceable to a named psychiatrist in a peer-reviewed journal, which is better than most circulating versions of it manage. But his published abstract identifies no data source for the figures — no market-research firm, no methodology — and the same author repeats the same numbers in a second paper, which is one source twice rather than two sources. Note also that the version circulating online, “over ¥90 billion by 2008,” is simply wrong: the published figure is ¥87 billion in 2006. And Ihara's opening words, “thanks to these marketing practices,” are a causal assertion, not a measurement.

What we are not going to tell you: that GlaxoSmithKline coined “kokoro no kaze.” The phrase — “a cold of the soul” — is the most quotable thing in this entire story, and we cannot source the claim that marketers invented it. The one scholarly source we found attributes the catchphrase to unnamed pharmaceutical companies and offers no evidence for the coinage [22]. No source we could reach documents its origin, and none rules out earlier colloquial use. A 2025 history of exactly this period does not mention the phrase at all [18]. So we report that a psychiatrist called it disease mongering, and we do not report who invented it, because nobody has shown us.

One more thing we could not stand up. Watters describes Western psychiatrists flown to an all-expenses-paid conference in Kyoto. The body he names is real and its output is real — the International Consensus Group on Depression and Anxiety published a consensus statement on transcultural issues in a 2001 supplement of the Journal of Clinical Psychiatry, with Laurence Kirmayer among the authors alongside two Japanese psychiatrists [23]. Journal supplements are frequently funded by industry. We could not retrieve this one's funding statement, so we do not assert that a drug company paid for it.

What survives, and it is still the point of this page. Drug marketing in Japan was real, was studied by an anthropologist while it happened, and coincided with a large expansion of a drug market. What the evidence does not support is the tidy version where marketers arrived first and produced a national mood. The public worry came first; the concept had a long local history; the courts did some of the work; and the marketing landed in ground already turned over. That is a more complicated story and a truer one — and it is a warning about how a vivid narrative travels further than the sequence of events that produced it.